A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Efficacy and Safety of Ethyl-Ester Omega-3 Fatty Acid in Taiwanese Hypertriglyceridemic Patients
Aim: Information regarding the effects of omega-3 fatty acid on hypertriglyceridemic patients in Chinese is still limited. This study aimed to investigate the efficacy and safety of Omacor®, a prescription ethyl-ester omega-3 fatty acid for the treatment of hypertriglyceridemia, administered at dose...
Saved in:
| Published in | Journal of Atherosclerosis and Thrombosis Vol. 24; no. 3; pp. 275 - 289 |
|---|---|
| Main Authors | , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Japan
Japan Atherosclerosis Society
01.01.2017
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1340-3478 1880-3873 1880-3873 |
| DOI | 10.5551/jat.34231 |
Cover
| Abstract | Aim: Information regarding the effects of omega-3 fatty acid on hypertriglyceridemic patients in Chinese is still limited. This study aimed to investigate the efficacy and safety of Omacor®, a prescription ethyl-ester omega-3 fatty acid for the treatment of hypertriglyceridemia, administered at doses of 2 g/day and 4 g/day to Taiwanese hypertriglyceridemic patients.Methods: A multicenter, randomized, double-blind, placebo-controlled, parallel study in adults with hypertriglyceridemia was conducted. After a five-week diet lead in period patients with triglycerides =200–1000 mg/dL were randomized to receive Omacor®, a concentrated preparation of omega-3 eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA) in a dose of 1 g twice daily (2 g Omacor®), 2 g twice daily (4 g Omacor®) or placebo, for eight weeks. The primary endpoint was the percentage change in triglyceride serum levels from baseline to the end of treatment.Results: A total of 253 Taiwanese patients were randomized, of which 65.6% (166) were men. At the end of the treatment, the percentage change in triglyceride serum levels in both the Omacor® 4 g/day (－32.1%) and 2 g/day (－29.7%) groups was larger than in the placebo group (－5.4%) (p＜0.001). The incidence of drug-related adverse events was as follows: 0.0%, 1.2%, and 0.0% in Omacor® 4 g/day, Omacor® 2 g/day, and placebo groups, respectively. No drug-related serious adverse events were reported during the study.Conclusions: Omacor® may be a feasible option to treat hypertriglyceridemia in Taiwanese patients. |
|---|---|
| AbstractList | Aim: Information regarding the effects of omega-3 fatty acid on hypertriglyceridemic patients in Chinese is still limited. This study aimed to investigate the efficacy and safety of Omacor®, a prescription ethyl-ester omega-3 fatty acid for the treatment of hypertriglyceridemia, administered at doses of 2 g/day and 4 g/day to Taiwanese hypertriglyceridemic patients. Methods: A multicenter, randomized, double-blind, placebo-controlled, parallel study in adults with hypertriglyceridemia was conducted. After a five-week diet lead in period patients with triglycerides = 200–1000 mg/dL were randomized to receive Omacor®, a concentrated preparation of omega-3 eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA) in a dose of 1 g twice daily (2 g Omacor ®), 2 g twice daily (4 g Omacor®) or placebo, for eight weeks. The primary endpoint was the percentage change in triglyceride serum levels from baseline to the end of treatment. Results: A total of 253 Taiwanese patients were randomized, of which 65.6% (166) were men. At the end of the treatment, the percentage change in triglyceride serum levels in both the Omacor® 4 g/day (−32.1%) and 2 g/day (−29.7%) groups was larger than in the placebo group (−5.4%) (p < 0.001). The incidence of drug-related adverse events was as follows: 0.0%, 1.2%, and 0.0% in Omacor ® 4 g/day, Omacor® 2 g/day, and placebo groups, respectively. No drug-related serious adverse events were reported during the study. Conclusions: Omacor® may be a feasible option to treat hypertriglyceridemia in Taiwanese patients. Information regarding the effects of omega-3 fatty acid on hypertriglyceridemic patients in Chinese is still limited. This study aimed to investigate the efficacy and safety of Omacor , a prescription ethyl-ester omega-3 fatty acid for the treatment of hypertriglyceridemia, administered at doses of 2 g/day and 4 g/day to Taiwanese hypertriglyceridemic patients. A multicenter, randomized, double-blind, placebo-controlled, parallel study in adults with hypertriglyceridemia was conducted. After a five-week diet lead in period patients with triglycerides =200-1000 mg/dL were randomized to receive Omacor , a concentrated preparation of omega-3 eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA) in a dose of 1 g twice daily (2 g Omacor ), 2 g twice daily (4 g Omacor ) or placebo, for eight weeks. The primary endpoint was the percentage change in triglyceride serum levels from baseline to the end of treatment. A total of 253 Taiwanese patients were randomized, of which 65.6% (166) were men. At the end of the treatment, the percentage change in triglyceride serum levels in both the Omacor 4 g/day (－32.1%) and 2 g/day (－29.7%) groups was larger than in the placebo group (－5.4%) (p＜0.001). The incidence of drug-related adverse events was as follows: 0.0%, 1.2%, and 0.0% in Omacor 4 g/day, Omacor 2 g/day, and placebo groups, respectively. No drug-related serious adverse events were reported during the study. Omacor may be a feasible option to treat hypertriglyceridemia in Taiwanese patients. Aim: Information regarding the effects of omega-3 fatty acid on hypertriglyceridemic patients in Chinese is still limited. This study aimed to investigate the efficacy and safety of Omacor(R), a prescription ethyl-ester omega-3 fatty acid for the treatment of hypertriglyceridemia, administered at doses of 2 g/day and 4 g/day to Taiwanese hypertriglyceridemic patients. Methods: A multicenter, randomized, double-blind, placebo-controlled, parallel study in adults with hypertriglyceridemia was conducted. After a five-week diet lead in period patients with triglycerides = 200 - 1000 mg/dL were randomized to receive Omacor(R), a concentrated preparation of omega-3 eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA) in a dose of 1 g twice daily (2 g Omacor(R)), 2 g twice daily (4 g Omacor(R)) or placebo, for eight weeks. The primary endpoint was the percentage change in triglyceride serum levels from baseline to the end of treatment. Results: A total of 253 Taiwanese patients were randomized, of which 65.6% (166) were men. At the end of the treatment, the percentage change in triglyceride serum levels in both the Omacor(R) 4 g/day (-32.1%) and 2 g/day (-29.7%) groups was larger than in the placebo group (-5.4%) (p < 0.001). The incidence of drug-related adverse events was as follows: 0.0%, 1.2%, and 0.0% in Omacor(R) 4 g/day, Omacor(R) 2 g/day, and placebo groups, respectively. No drug-related serious adverse events were reported during the study. Conclusions: Omacor(R) may be a feasible option to treat hypertriglyceridemia in Taiwanese patients. Aim: Information regarding the effects of omega-3 fatty acid on hypertriglyceridemic patients in Chinese is still limited. This study aimed to investigate the efficacy and safety of Omacor®, a prescription ethyl-ester omega-3 fatty acid for the treatment of hypertriglyceridemia, administered at doses of 2 g/day and 4 g/day to Taiwanese hypertriglyceridemic patients.Methods: A multicenter, randomized, double-blind, placebo-controlled, parallel study in adults with hypertriglyceridemia was conducted. After a five-week diet lead in period patients with triglycerides =200–1000 mg/dL were randomized to receive Omacor®, a concentrated preparation of omega-3 eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA) in a dose of 1 g twice daily (2 g Omacor®), 2 g twice daily (4 g Omacor®) or placebo, for eight weeks. The primary endpoint was the percentage change in triglyceride serum levels from baseline to the end of treatment.Results: A total of 253 Taiwanese patients were randomized, of which 65.6% (166) were men. At the end of the treatment, the percentage change in triglyceride serum levels in both the Omacor® 4 g/day (－32.1%) and 2 g/day (－29.7%) groups was larger than in the placebo group (－5.4%) (p＜0.001). The incidence of drug-related adverse events was as follows: 0.0%, 1.2%, and 0.0% in Omacor® 4 g/day, Omacor® 2 g/day, and placebo groups, respectively. No drug-related serious adverse events were reported during the study.Conclusions: Omacor® may be a feasible option to treat hypertriglyceridemia in Taiwanese patients. Information regarding the effects of omega-3 fatty acid on hypertriglyceridemic patients in Chinese is still limited. This study aimed to investigate the efficacy and safety of Omacor®, a prescription ethyl-ester omega-3 fatty acid for the treatment of hypertriglyceridemia, administered at doses of 2 g/day and 4 g/day to Taiwanese hypertriglyceridemic patients.AIMInformation regarding the effects of omega-3 fatty acid on hypertriglyceridemic patients in Chinese is still limited. This study aimed to investigate the efficacy and safety of Omacor®, a prescription ethyl-ester omega-3 fatty acid for the treatment of hypertriglyceridemia, administered at doses of 2 g/day and 4 g/day to Taiwanese hypertriglyceridemic patients.A multicenter, randomized, double-blind, placebo-controlled, parallel study in adults with hypertriglyceridemia was conducted. After a five-week diet lead in period patients with triglycerides =200-1000 mg/dL were randomized to receive Omacor®, a concentrated preparation of omega-3 eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA) in a dose of 1 g twice daily (2 g Omacor®), 2 g twice daily (4 g Omacor®) or placebo, for eight weeks. The primary endpoint was the percentage change in triglyceride serum levels from baseline to the end of treatment.METHODSA multicenter, randomized, double-blind, placebo-controlled, parallel study in adults with hypertriglyceridemia was conducted. After a five-week diet lead in period patients with triglycerides =200-1000 mg/dL were randomized to receive Omacor®, a concentrated preparation of omega-3 eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA) in a dose of 1 g twice daily (2 g Omacor®), 2 g twice daily (4 g Omacor®) or placebo, for eight weeks. The primary endpoint was the percentage change in triglyceride serum levels from baseline to the end of treatment.A total of 253 Taiwanese patients were randomized, of which 65.6% (166) were men. At the end of the treatment, the percentage change in triglyceride serum levels in both the Omacor® 4 g/day (－32.1%) and 2 g/day (－29.7%) groups was larger than in the placebo group (－5.4%) (p＜0.001). The incidence of drug-related adverse events was as follows: 0.0%, 1.2%, and 0.0% in Omacor® 4 g/day, Omacor® 2 g/day, and placebo groups, respectively. No drug-related serious adverse events were reported during the study.RESULTSA total of 253 Taiwanese patients were randomized, of which 65.6% (166) were men. At the end of the treatment, the percentage change in triglyceride serum levels in both the Omacor® 4 g/day (－32.1%) and 2 g/day (－29.7%) groups was larger than in the placebo group (－5.4%) (p＜0.001). The incidence of drug-related adverse events was as follows: 0.0%, 1.2%, and 0.0% in Omacor® 4 g/day, Omacor® 2 g/day, and placebo groups, respectively. No drug-related serious adverse events were reported during the study.Omacor® may be a feasible option to treat hypertriglyceridemia in Taiwanese patients.CONCLUSIONSOmacor® may be a feasible option to treat hypertriglyceridemia in Taiwanese patients. |
| Author | Tsai, Wei-Chuan Charng, Min-Ji Su, Ta-Chen Hwang, Juey-Jen Huang, Kuo-Chin Chiang, Fu-Tien Wang, Kuo-Yang Lin, Lian-Yu Tseng, Chuen-Den Chien, Kuo-Liong Vige, Runar Olivar, José Emilio Ruiz |
| Author_xml | – sequence: 1 fullname: Chiang, Fu-Tien organization: Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital – sequence: 1 fullname: Hwang, Juey-Jen organization: Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital – sequence: 1 fullname: Huang, Kuo-Chin organization: Department of Family Medicine, National Taiwan University Hospital – sequence: 1 fullname: Wang, Kuo-Yang organization: Cardiovascular Center and Department of Anesthesiology, Taichung Veterans General Hospital – sequence: 1 fullname: Su, Ta-Chen organization: Institute of Occupational Medicine and Industrial Hygiene, National Taiwan University College of Public Health – sequence: 1 fullname: Lin, Lian-Yu organization: Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital – sequence: 1 fullname: Olivar, José Emilio Ruiz organization: Ferrer Group – sequence: 1 fullname: Tsai, Wei-Chuan organization: Division of Cardiology, Internal Medicine, National Cheng Kung University Hospital – sequence: 1 fullname: Chien, Kuo-Liong organization: Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University – sequence: 1 fullname: Charng, Min-Ji organization: Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital – sequence: 1 fullname: Vige, Runar organization: Pronova Biopharma Norge AS – sequence: 1 fullname: Tseng, Chuen-Den organization: Division of Cardiology, Department of Internal Medicine, Shin Kong Wu Ho-Su Memorial Hospital |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27600795$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9UtuO0zAQjdAi9gIP_ADyIyCy60sSJy-gUrq7SCvtCpZna-pMWlduXGyXJXwTH4nbLuUihCKNbc2ZcyZn5jg76F2PWfaU0dOyLNnZAuKpKLhgD7IjVtc0F7UUB-kuinQvZH2YHYewoFSIsuSPskMuK0plUx5l30fkA_StW5pv2L4i79x6ajF_a02fXjcWNE5dPnZ99M5abMk4ZYwGS269STE6MgoBQyBxjmTSdSmnB5IYyUfoMA7EdWQS54PNJyGiJ9dLnEEuyDnElBxp0xLTk1swd9BjQHI5rNBHb2Z20OhNi0ujyQ1Eg30Mj7OHHdiAT-7Pk-zT-eR2fJlfXV-8H4-ucl3VVcx5KVrWSDmt66aSLWMU0tdISjWrOmCcNw1D3YkWpMSumk5pBQBNCZwxXjfiJHu54133KxjuwFq18mYJflCMqo3lKlmutpYn8OsdeLWeLrHVqVEPvwocGPVnpjdzNXNfVClqURZFInh-T-Dd5zWGqJYmaLQ2OeLWQbG6bCSXtOIJ-ux3rb3Iz3kmwIsdQHsXgsfuv42f_YXVJianN8MGY_9ZcbGrSNqbJXB92gZUC7f2fZqHwq8ybdIAilMmFaW8oCIdjaJclinUDa8FrcrNj7zZMS1ChBnuuwQfjba41eSFEtuw0d5n9By8wl78AJlg73o |
| CitedBy_id | crossref_primary_10_1016_j_ajcnut_2023_03_025 crossref_primary_10_1016_j_advnut_2023_08_003 crossref_primary_10_1038_s41598_020_72686_0 crossref_primary_10_3390_nu14051104 crossref_primary_10_3390_nu10101460 crossref_primary_10_1038_s41430_020_00709_0 crossref_primary_10_1515_jpem_2018_0409 crossref_primary_10_5551_jat_ED063 crossref_primary_10_1016_j_plefa_2018_01_001 crossref_primary_10_3389_fnut_2022_1039056 crossref_primary_10_1161_JAHA_123_029512 crossref_primary_10_3390_nu15051088 |
| Cites_doi | 10.1016/S0021-9150(99)00267-1 10.1093/eurheartj/ehr112 10.1016/j.amjcard.2005.12.024 10.1111/1755-5922.12146 10.1016/S0002-9149(97)89130-8 10.1016/S0753-3322(02)00253-6 10.1161/01.ATV.0000057393.97337.AE 10.1007/s12325-009-0045-2 10.1016/j.amjcard.2009.12.063 10.1016/j.jacl.2013.09.002 10.1136/heart.85.5.544 10.1016/j.amjcard.2008.03.078 10.1016/j.clinthera.2007.07.018 10.2169/internalmedicine.47.0696 10.1001/jama.1988.03410130125037 10.1016/0026-0495(84)90230-0 10.5551/jat.19976 10.1016/j.cca.2012.10.054 10.1517/14656566.9.7.1237 10.1185/03007991003645318 10.1161/CIR.0b013e3182160726 10.5551/jat.21022 10.1016/S0021-9150(98)00301-3 10.1186/1476-511X-13-179 10.1042/bj3430191 10.1016/j.jacl.2013.01.006 10.1097/00043798-199710000-00011 10.1016/j.jacl.2009.08.001 10.1079/BJN2002556 10.1016/j.amjcard.2005.12.025 |
| ContentType | Journal Article |
| Copyright | 2017 This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License. 2017 Japan Atherosclerosis Society 2017 |
| Copyright_xml | – notice: 2017 This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License. – notice: 2017 Japan Atherosclerosis Society 2017 |
| CorporateAuthor | National Taiwan University Hospital Taichung Veterans General Hospital National Taiwan University Department of Internal Medicine National Cheng Kung University Hospital Department of Medicine Internal Medicine National Taiwan University College of Public Health Department of Family Medicine Institute of Epidemiology and Preventive Medicine College of Public Health Institute of Occupational Medicine and Industrial Hygiene Division of Cardiology Taipei Veterans General Hospital Ferrer Group Shin Kong Wu Ho-Su Memorial Hospital Cardiovascular Center and Department of Anesthesiology Pronova Biopharma Norge AS |
| CorporateAuthor_xml | – name: Cardiovascular Center and Department of Anesthesiology – name: Department of Medicine – name: Taipei Veterans General Hospital – name: Pronova Biopharma Norge AS – name: Ferrer Group – name: Institute of Epidemiology and Preventive Medicine – name: College of Public Health – name: Department of Internal Medicine – name: National Cheng Kung University Hospital – name: Shin Kong Wu Ho-Su Memorial Hospital – name: Internal Medicine – name: Institute of Occupational Medicine and Industrial Hygiene – name: Department of Family Medicine – name: National Taiwan University – name: National Taiwan University College of Public Health – name: Taichung Veterans General Hospital – name: Division of Cardiology – name: National Taiwan University Hospital |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM ADTOC UNPAY |
| DOI | 10.5551/jat.34231 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1880-3873 |
| EndPage | 289 |
| ExternalDocumentID | 10.5551/jat.34231 PMC5383544 27600795 10_5551_jat_34231 ex7domya_2017_002403_009_0275_02892830652 article_jat_24_3_24_34231_article_char_en |
| Genre | Randomized Controlled Trial Multicenter Study Journal Article |
| GroupedDBID | --- .55 29J 2WC 53G 5GY 5VS AAFWJ ACGFO ADBBV AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL DIK DU5 E3Z F5P GX1 HYE JMI JSF JSH KQ8 OK1 OVT P6G RJT RNS RPM RZJ TR2 X7M 3O- TKC AAYXX CITATION CGR CUY CVF ECM EIF GROUPED_DOAJ M~E NPM 7X8 5PM ADTOC UNPAY |
| ID | FETCH-LOGICAL-c686t-253d1977b88967d110a0a09700c16fa122991ecf3da77ef6bb06aaa95a2112893 |
| IEDL.DBID | UNPAY |
| ISSN | 1340-3478 1880-3873 |
| IngestDate | Wed Aug 20 00:12:44 EDT 2025 Tue Sep 30 16:49:19 EDT 2025 Thu Jul 10 19:05:41 EDT 2025 Thu Jan 02 22:19:13 EST 2025 Tue Jul 01 02:27:09 EDT 2025 Thu Apr 24 23:07:25 EDT 2025 Thu Jul 10 16:15:07 EDT 2025 Wed Sep 03 06:30:29 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 3 |
| Language | English |
| License | https://creativecommons.org/licenses/by-nc-sa/4.0/deed.ja This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License.http://creativecommons.org/licenses/by-nc-sa/3.0 cc-by-nc-sa |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c686t-253d1977b88967d110a0a09700c16fa122991ecf3da77ef6bb06aaa95a2112893 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://www.jstage.jst.go.jp/article/jat/24/3/24_34231/_pdf |
| PMID | 27600795 |
| PQID | 1859727062 |
| PQPubID | 23479 |
| PageCount | 15 |
| ParticipantIDs | unpaywall_primary_10_5551_jat_34231 pubmedcentral_primary_oai_pubmedcentral_nih_gov_5383544 proquest_miscellaneous_1859727062 pubmed_primary_27600795 crossref_primary_10_5551_jat_34231 crossref_citationtrail_10_5551_jat_34231 medicalonline_journals_ex7domya_2017_002403_009_0275_02892830652 jstage_primary_article_jat_24_3_24_34231_article_char_en |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2017-01-01 |
| PublicationDateYYYYMMDD | 2017-01-01 |
| PublicationDate_xml | – month: 01 year: 2017 text: 2017-01-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Japan |
| PublicationPlace_xml | – name: Japan |
| PublicationTitle | Journal of Atherosclerosis and Thrombosis |
| PublicationTitleAlternate | JAT |
| PublicationYear | 2017 |
| Publisher | Japan Atherosclerosis Society |
| Publisher_xml | – name: Japan Atherosclerosis Society |
| References | 15) Bradberry JC, Hilleman DE: Overview of omega-3 Fatty Acid therapies. P T, 2013; 38: 681-691 32) Kohashi K, Nakagomi A, Saiki Y, Morisawa T, et al.: Effects of eicosapentaenoic acid on the levels of inflammatory markers, cardiac function and long-term prognosis in chronic heart failure patients with dyslipidemia. J Atheroscler Thromb, 2014; 21: 712-729 19) Lee MJ, Chien KL, Chen MF, Stephenson DA, Su TC: Overweight modulates APOE and APOA5 alleles on the risk of severe hypertriglyceridemia. Clin Chim Acta, 2013; 416: 31-35 30) Ding C, Hsu SH, Wu YJ, Su TC: Additive effects of postchallenge hyperglycemia and low-density lipoprotein particles on the risk of arterial stiffness in healthy adults. Lipids Health Dis, 2014; 13: 179 3) Skulas-Ray AC, West SG, Davidson MH, Kris-Etherton PM: Omega-3 fatty acid concentrates in the treatment of moderate hypertriglyceridemia. Expert Opin Pharmacother, 2008; 9: 1237-1248 7) Berge RK, Madsen L, Vaagenes H, Tronstad KJ, Gottlicher M, Rustan AC: In contrast with docosahexaenoic acid, eicosapentaenoic acid and hypolipidaemic derivatives decrease hepatic synthesis and secretion of triacylglycerol by decreased diacylglycerol acyltransferase activity and stimulation of fatty acid oxidation. Biochem J, 1999; 343: 191-197 4) Kris-Etherton PM, Harris WS, Appel LJ: Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arterioscler Thromb Vasc Biol, 2003; 23: 151-152 29) Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM: Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA, 1988; 260: 1917-1921 18) Lin CY, Chen MF, Lin LY, Liau CS, Lee YT, Su TC: Insulin resistance is the major determinant for microalbuminuria in severe hypertriglyceridemia: Implication for high-risk stratification. Int Med, 2008; 47: 1091-1097 21) Davidson MH, Maki KC, Bays H, Carter R, Ballantyne CM: Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A(2) mass in statin-treated subjects with hypertriglyceridemia. J Clin Lipidol, 2009; 3: 332-340 24) Leigh-Firbank EC, Minihane AM, Leake DS, Wright JW, Murphy MC, Griffin BA, et al.: Eicosapentaenoic acid and docosahexaenoic acid from fish oils: differential associations with lipid responses. Br J Nutr, 2002; 87: 435-445 9) Davidson MH, Stein EA, Bays HE, Maki KC, Doyle RT, Shalwitz RA, et al.: Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther, 2007; 29: 1354-1367 1) Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, et al.: Triglycerides and cardiovascular dis ease: a scientific statement from the American Heart Association. Circulation, 2011; 123: 2292-2333 14) Balk E, Chung M, Lichtenstein A, Chew P, Kupelnick B, Lawrence A, et al.: Effects of omega-3 fatty acids on cardiovascular risk factors and intermediate markers of cardiovascular disease. Evid Rep Technol Assess (Summ), 2004; 93: 1-6 8) Nambi V, Ballantyne CM: Combination therapy with statins and omega-3 fatty acids. Am J Cardiol, 2006; 98(4A): 34i-38i 27) Maki KC, McKenney JM, Reeves MS, Lubin BC, Dicklin MR: Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia. Am J Cardiol, 2008; 102: 429-433 5) Rupp H: Omacor (prescription omega-3-acid ethyl esters 90): From severe rhythm disorders to hypertriglyceridemia. Adv Ther, 2009; 26: 675-690 28) Tatsuno I, Kudou K, Kagawa T: Effect of TAK-085 on low-density lipoprotein particle size in patients with hypertriglyceridemia: A double-blind randomized clinical study. Cardiovasc Ther, 2015; 33: 317-323 31) Bays HE, Maki KC, McKenney J, Snipes R, Meadowcroft A, Schroyer R, et al.: Long-term up to 24-month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients. Curr Med Res Opin, 2010; 26: 907-915 13) Durrington PN, Bhatnagar D, Mackness MI, Morgan J, Julier K, Khan MA, et al.: An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart, 2001; 85: 544-548 23) Eritsland J, Arnesen H, Gronseth K, Fjeld NB, Abdelnoor M: Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency. Am J Cardiol, 1996; 77: 31-36 17) Simopoulos AP: The importance of the ratio of omega-6/omega-3 essential faty acids. Biomed & Pharmacother, 2002; 56: 365-379 20) Ito R, Satoh-Asahara N, Yamakage H, Sasaki Y, et al.: An increase in the EPA/AA ratio is associated with improved arterial stiffness in obese patients with dyslipidemia. J Atheroscler Thromb, 2014; 21: 248-260 26) Tatsuno I, Saito Y, Ootake J: Long-term safety and efficacy of TAK-085 in Japanese subjects with hypertriglycer-idemia undergoing lifestyle modification: The omega-3 fatty acids randomized long-term (ORL) study. J Clin Lipidol, 2013; 7: 615-625 12) Harris WS, Ginsberg HN, Arunakul N, Shachter NS, Windsor SL, Adams M, et al.: Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk, 1997; 4: 385-391 11) Pownall HJ, Brauchi D, Kilinc C, Osmundsen K, Pao Q, Payton-Ross C, et al.: Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis, 1999; 143: 285-297 25) Maki KC, Dicklin MR, Davidson MH, Doyle RT, Ballantyne CM: Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to simvastatin therapy. Am J Cardiol, 2010; 105: 1409-1412 16) Harris WS, Connor WE, Inkeles SB, Illingworth DR: Dietary omega-3 fatty acids prevent carbohydrate-induced hypertriglyceridemia. Metabolism, 1984; 33: 1016-1019 2) Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Boren J, Catapano AL, et al.: Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J, 2011; 32: 1345-1361 6) Davidson MH: Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am J Cardiol, 2006; 98(4A): 27i-33i 10) Tatsuno I, Saito Y, Kudou K, Ootake J: Efficacy and safety of TAK-085 compared with eicosapentaenoic acid in Japanese subjects with hypertriglyceridemia undergoing lifestyl modification: The omega-3 fatty acids randomized double-blind (ORD) study. J Clin Lipidol, 2013; 7: 199-207 22) Calabresi L, Donati D, Pazzucconi F, Sirtori CR, Franceschini G: Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses. Atherosclerosis, 2000; 148: 387-396 22 23 24 25 26 27 28 29 30 31 10 32 11 12 13 14 15 16 17 18 19 1 2 3 4 5 6 7 8 9 20 21 23178747 - Clin Chim Acta. 2013 Feb 1;416:31-5 17825687 - Clin Ther. 2007 Jul;29(7):1354-67 20451686 - Am J Cardiol. 2010 May 15;105(10):1409-12 18422480 - Expert Opin Pharmacother. 2008 May;9(7):1237-48 12010583 - Br J Nutr. 2002 May;87(5):435-45 10217357 - Atherosclerosis. 1999 Apr;143(2):285-97 16919514 - Am J Cardiol. 2006 Aug 21;98(4A):27i-33i 26222126 - Cardiovasc Ther. 2015 Dec;33(6):317-23 19629408 - Adv Ther. 2009 Jul;26(7):675-90 8540453 - Am J Cardiol. 1996 Jan 1;77(1):31-6 24670266 - J Atheroscler Thromb. 2014;21(7):712-29 12442909 - Biomed Pharmacother. 2002 Oct;56(8):365-79 21291831 - J Clin Lipidol. 2009 Oct;3(5):332-40 9865671 - J Cardiovasc Risk. 1997 Oct-Dec;4(5-6):385-91 24270918 - J Atheroscler Thromb. 2014;21(3):248-60 20156032 - Curr Med Res Opin. 2010 Apr;26(4):907-15 24314359 - J Clin Lipidol. 2013 Nov-Dec;7(6):615-25 11303007 - Heart. 2001 May;85(5):544-8 18678300 - Am J Cardiol. 2008 Aug 15;102(4):429-33 21502576 - Circulation. 2011 May 24;123(20):2292-333 16919515 - Am J Cardiol. 2006 Aug 21;98(4A):34i-38i 18552465 - Intern Med. 2008;47(12):1091-7 3418853 - JAMA. 1988 Oct 7;260(13):1917-21 10493929 - Biochem J. 1999 Oct 1;343 Pt 1:191-7 6493044 - Metabolism. 1984 Nov;33(11):1016-9 15133887 - Evid Rep Technol Assess (Summ). 2004 Mar;(93):1-6 10657575 - Atherosclerosis. 2000 Feb;148(2):387-96 12588750 - Arterioscler Thromb Vasc Biol. 2003 Feb 1;23(2):151-2 25431283 - Lipids Health Dis. 2014 Nov 27;13:179 23725919 - J Clin Lipidol. 2013 May-Jun;7(3):199-207 24391388 - P T. 2013 Nov;38(11):681-91 21531743 - Eur Heart J. 2011 Jun;32(11):1345-61 |
| References_xml | – reference: 13) Durrington PN, Bhatnagar D, Mackness MI, Morgan J, Julier K, Khan MA, et al.: An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart, 2001; 85: 544-548 – reference: 9) Davidson MH, Stein EA, Bays HE, Maki KC, Doyle RT, Shalwitz RA, et al.: Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther, 2007; 29: 1354-1367 – reference: 6) Davidson MH: Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am J Cardiol, 2006; 98(4A): 27i-33i – reference: 26) Tatsuno I, Saito Y, Ootake J: Long-term safety and efficacy of TAK-085 in Japanese subjects with hypertriglycer-idemia undergoing lifestyle modification: The omega-3 fatty acids randomized long-term (ORL) study. J Clin Lipidol, 2013; 7: 615-625 – reference: 3) Skulas-Ray AC, West SG, Davidson MH, Kris-Etherton PM: Omega-3 fatty acid concentrates in the treatment of moderate hypertriglyceridemia. Expert Opin Pharmacother, 2008; 9: 1237-1248 – reference: 22) Calabresi L, Donati D, Pazzucconi F, Sirtori CR, Franceschini G: Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses. Atherosclerosis, 2000; 148: 387-396 – reference: 7) Berge RK, Madsen L, Vaagenes H, Tronstad KJ, Gottlicher M, Rustan AC: In contrast with docosahexaenoic acid, eicosapentaenoic acid and hypolipidaemic derivatives decrease hepatic synthesis and secretion of triacylglycerol by decreased diacylglycerol acyltransferase activity and stimulation of fatty acid oxidation. Biochem J, 1999; 343: 191-197 – reference: 1) Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, et al.: Triglycerides and cardiovascular dis ease: a scientific statement from the American Heart Association. Circulation, 2011; 123: 2292-2333 – reference: 24) Leigh-Firbank EC, Minihane AM, Leake DS, Wright JW, Murphy MC, Griffin BA, et al.: Eicosapentaenoic acid and docosahexaenoic acid from fish oils: differential associations with lipid responses. Br J Nutr, 2002; 87: 435-445 – reference: 31) Bays HE, Maki KC, McKenney J, Snipes R, Meadowcroft A, Schroyer R, et al.: Long-term up to 24-month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients. Curr Med Res Opin, 2010; 26: 907-915 – reference: 25) Maki KC, Dicklin MR, Davidson MH, Doyle RT, Ballantyne CM: Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to simvastatin therapy. Am J Cardiol, 2010; 105: 1409-1412 – reference: 12) Harris WS, Ginsberg HN, Arunakul N, Shachter NS, Windsor SL, Adams M, et al.: Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk, 1997; 4: 385-391 – reference: 11) Pownall HJ, Brauchi D, Kilinc C, Osmundsen K, Pao Q, Payton-Ross C, et al.: Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis, 1999; 143: 285-297 – reference: 17) Simopoulos AP: The importance of the ratio of omega-6/omega-3 essential faty acids. Biomed & Pharmacother, 2002; 56: 365-379 – reference: 8) Nambi V, Ballantyne CM: Combination therapy with statins and omega-3 fatty acids. Am J Cardiol, 2006; 98(4A): 34i-38i – reference: 16) Harris WS, Connor WE, Inkeles SB, Illingworth DR: Dietary omega-3 fatty acids prevent carbohydrate-induced hypertriglyceridemia. Metabolism, 1984; 33: 1016-1019 – reference: 14) Balk E, Chung M, Lichtenstein A, Chew P, Kupelnick B, Lawrence A, et al.: Effects of omega-3 fatty acids on cardiovascular risk factors and intermediate markers of cardiovascular disease. Evid Rep Technol Assess (Summ), 2004; 93: 1-6 – reference: 27) Maki KC, McKenney JM, Reeves MS, Lubin BC, Dicklin MR: Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia. Am J Cardiol, 2008; 102: 429-433 – reference: 10) Tatsuno I, Saito Y, Kudou K, Ootake J: Efficacy and safety of TAK-085 compared with eicosapentaenoic acid in Japanese subjects with hypertriglyceridemia undergoing lifestyl modification: The omega-3 fatty acids randomized double-blind (ORD) study. J Clin Lipidol, 2013; 7: 199-207 – reference: 2) Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Boren J, Catapano AL, et al.: Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J, 2011; 32: 1345-1361 – reference: 20) Ito R, Satoh-Asahara N, Yamakage H, Sasaki Y, et al.: An increase in the EPA/AA ratio is associated with improved arterial stiffness in obese patients with dyslipidemia. J Atheroscler Thromb, 2014; 21: 248-260 – reference: 28) Tatsuno I, Kudou K, Kagawa T: Effect of TAK-085 on low-density lipoprotein particle size in patients with hypertriglyceridemia: A double-blind randomized clinical study. Cardiovasc Ther, 2015; 33: 317-323 – reference: 23) Eritsland J, Arnesen H, Gronseth K, Fjeld NB, Abdelnoor M: Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency. Am J Cardiol, 1996; 77: 31-36 – reference: 4) Kris-Etherton PM, Harris WS, Appel LJ: Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arterioscler Thromb Vasc Biol, 2003; 23: 151-152 – reference: 32) Kohashi K, Nakagomi A, Saiki Y, Morisawa T, et al.: Effects of eicosapentaenoic acid on the levels of inflammatory markers, cardiac function and long-term prognosis in chronic heart failure patients with dyslipidemia. J Atheroscler Thromb, 2014; 21: 712-729 – reference: 21) Davidson MH, Maki KC, Bays H, Carter R, Ballantyne CM: Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A(2) mass in statin-treated subjects with hypertriglyceridemia. J Clin Lipidol, 2009; 3: 332-340 – reference: 30) Ding C, Hsu SH, Wu YJ, Su TC: Additive effects of postchallenge hyperglycemia and low-density lipoprotein particles on the risk of arterial stiffness in healthy adults. Lipids Health Dis, 2014; 13: 179 – reference: 15) Bradberry JC, Hilleman DE: Overview of omega-3 Fatty Acid therapies. P T, 2013; 38: 681-691 – reference: 5) Rupp H: Omacor (prescription omega-3-acid ethyl esters 90): From severe rhythm disorders to hypertriglyceridemia. Adv Ther, 2009; 26: 675-690 – reference: 18) Lin CY, Chen MF, Lin LY, Liau CS, Lee YT, Su TC: Insulin resistance is the major determinant for microalbuminuria in severe hypertriglyceridemia: Implication for high-risk stratification. Int Med, 2008; 47: 1091-1097 – reference: 19) Lee MJ, Chien KL, Chen MF, Stephenson DA, Su TC: Overweight modulates APOE and APOA5 alleles on the risk of severe hypertriglyceridemia. Clin Chim Acta, 2013; 416: 31-35 – reference: 29) Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM: Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA, 1988; 260: 1917-1921 – ident: 22 doi: 10.1016/S0021-9150(99)00267-1 – ident: 2 doi: 10.1093/eurheartj/ehr112 – ident: 6 doi: 10.1016/j.amjcard.2005.12.024 – ident: 28 doi: 10.1111/1755-5922.12146 – ident: 23 doi: 10.1016/S0002-9149(97)89130-8 – ident: 17 doi: 10.1016/S0753-3322(02)00253-6 – ident: 14 – ident: 4 doi: 10.1161/01.ATV.0000057393.97337.AE – ident: 5 doi: 10.1007/s12325-009-0045-2 – ident: 25 doi: 10.1016/j.amjcard.2009.12.063 – ident: 26 doi: 10.1016/j.jacl.2013.09.002 – ident: 13 doi: 10.1136/heart.85.5.544 – ident: 27 doi: 10.1016/j.amjcard.2008.03.078 – ident: 9 doi: 10.1016/j.clinthera.2007.07.018 – ident: 18 doi: 10.2169/internalmedicine.47.0696 – ident: 29 doi: 10.1001/jama.1988.03410130125037 – ident: 16 doi: 10.1016/0026-0495(84)90230-0 – ident: 20 doi: 10.5551/jat.19976 – ident: 19 doi: 10.1016/j.cca.2012.10.054 – ident: 3 doi: 10.1517/14656566.9.7.1237 – ident: 31 doi: 10.1185/03007991003645318 – ident: 1 doi: 10.1161/CIR.0b013e3182160726 – ident: 32 doi: 10.5551/jat.21022 – ident: 15 – ident: 11 doi: 10.1016/S0021-9150(98)00301-3 – ident: 30 doi: 10.1186/1476-511X-13-179 – ident: 7 doi: 10.1042/bj3430191 – ident: 10 doi: 10.1016/j.jacl.2013.01.006 – ident: 12 doi: 10.1097/00043798-199710000-00011 – ident: 21 doi: 10.1016/j.jacl.2009.08.001 – ident: 24 doi: 10.1079/BJN2002556 – ident: 8 doi: 10.1016/j.amjcard.2005.12.025 – reference: 16919515 - Am J Cardiol. 2006 Aug 21;98(4A):34i-38i – reference: 15133887 - Evid Rep Technol Assess (Summ). 2004 Mar;(93):1-6 – reference: 23178747 - Clin Chim Acta. 2013 Feb 1;416:31-5 – reference: 3418853 - JAMA. 1988 Oct 7;260(13):1917-21 – reference: 10217357 - Atherosclerosis. 1999 Apr;143(2):285-97 – reference: 12442909 - Biomed Pharmacother. 2002 Oct;56(8):365-79 – reference: 26222126 - Cardiovasc Ther. 2015 Dec;33(6):317-23 – reference: 10657575 - Atherosclerosis. 2000 Feb;148(2):387-96 – reference: 20156032 - Curr Med Res Opin. 2010 Apr;26(4):907-15 – reference: 18552465 - Intern Med. 2008;47(12):1091-7 – reference: 21502576 - Circulation. 2011 May 24;123(20):2292-333 – reference: 8540453 - Am J Cardiol. 1996 Jan 1;77(1):31-6 – reference: 24314359 - J Clin Lipidol. 2013 Nov-Dec;7(6):615-25 – reference: 6493044 - Metabolism. 1984 Nov;33(11):1016-9 – reference: 11303007 - Heart. 2001 May;85(5):544-8 – reference: 21531743 - Eur Heart J. 2011 Jun;32(11):1345-61 – reference: 25431283 - Lipids Health Dis. 2014 Nov 27;13:179 – reference: 12588750 - Arterioscler Thromb Vasc Biol. 2003 Feb 1;23(2):151-2 – reference: 24270918 - J Atheroscler Thromb. 2014;21(3):248-60 – reference: 23725919 - J Clin Lipidol. 2013 May-Jun;7(3):199-207 – reference: 18422480 - Expert Opin Pharmacother. 2008 May;9(7):1237-48 – reference: 19629408 - Adv Ther. 2009 Jul;26(7):675-90 – reference: 12010583 - Br J Nutr. 2002 May;87(5):435-45 – reference: 18678300 - Am J Cardiol. 2008 Aug 15;102(4):429-33 – reference: 9865671 - J Cardiovasc Risk. 1997 Oct-Dec;4(5-6):385-91 – reference: 21291831 - J Clin Lipidol. 2009 Oct;3(5):332-40 – reference: 16919514 - Am J Cardiol. 2006 Aug 21;98(4A):27i-33i – reference: 24670266 - J Atheroscler Thromb. 2014;21(7):712-29 – reference: 17825687 - Clin Ther. 2007 Jul;29(7):1354-67 – reference: 20451686 - Am J Cardiol. 2010 May 15;105(10):1409-12 – reference: 10493929 - Biochem J. 1999 Oct 1;343 Pt 1:191-7 – reference: 24391388 - P T. 2013 Nov;38(11):681-91 |
| SSID | ssj0033552 ssib002822083 |
| Score | 2.2030678 |
| Snippet | Aim: Information regarding the effects of omega-3 fatty acid on hypertriglyceridemic patients in Chinese is still limited. This study aimed to investigate the... Information regarding the effects of omega-3 fatty acid on hypertriglyceridemic patients in Chinese is still limited. This study aimed to investigate the... |
| SourceID | unpaywall pubmedcentral proquest pubmed crossref medicalonline jstage |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 275 |
| SubjectTerms | Adult Dietary Supplements Docosahexaenoic acid Docosahexaenoic Acids - therapeutic use Double-Blind Method Drug Combinations Eicosapentaenoic acid Eicosapentaenoic Acid - therapeutic use Ethnic chinese Fatty Acids, Omega-3 - administration & dosage Female Humans Hypertriglyceridemia Hypertriglyceridemia - drug therapy Hypertriglyceridemia - pathology Hypolipidemic Agents - therapeutic use Life Style Male Middle Aged Omacor Omega-3 fatty acids Original Safety Severity of Illness Index Taiwan Treatment Outcome Triglycerides - blood |
| Title | A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Efficacy and Safety of Ethyl-Ester Omega-3 Fatty Acid in Taiwanese Hypertriglyceridemic Patients |
| URI | https://www.jstage.jst.go.jp/article/jat/24/3/24_34231/_article/-char/en http://mol.medicalonline.jp/en/journal/download?GoodsID=ex7domya/2017/002403/009&name=0275-0289e https://www.ncbi.nlm.nih.gov/pubmed/27600795 https://www.proquest.com/docview/1859727062 https://pubmed.ncbi.nlm.nih.gov/PMC5383544 https://www.jstage.jst.go.jp/article/jat/24/3/24_34231/_pdf |
| UnpaywallVersion | publishedVersion |
| Volume | 24 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Journal of Atherosclerosis and Thrombosis, 2017/03/01, Vol.24(3), pp.275-289 |
| journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1880-3873 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0033552 issn: 1880-3873 databaseCode: KQ8 dateStart: 20160101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1880-3873 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0033552 issn: 1880-3873 databaseCode: KQ8 dateStart: 20020101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1880-3873 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0033552 issn: 1880-3873 databaseCode: KQ8 dateStart: 19940101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1880-3873 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0033552 issn: 1880-3873 databaseCode: DIK dateStart: 20020101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1880-3873 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0033552 issn: 1880-3873 databaseCode: GX1 dateStart: 20020101 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 1880-3873 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0033552 issn: 1880-3873 databaseCode: RPM dateStart: 20160101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bi9NAFB52u-IF8X6Jl2W8PPhg2iaTTBp8sS6tRXBdtIUKwjCZTGprmpQ2Ze3-Jn-k52TSYHUFkUJDmcOkk3OZb3LOfEPIcx0yL2FIORsqZnucg8_5WtoJSwA-SFfHScn2ecwHI-_d2B_vkVfbvTBYVjkDXDTReGlO8uZs0aoeYmsmYbHutRh8CWSuc1piESf75IBjdqlBDkbHJ93P5RLLg-jilXEYCceQQZYZXiEfIAJ21Cw72JmNLpgbXyFX5yZJYsgqzsOef5ZQXlpnC7k5lWn6y_zUv06-bEdmylK-NddF1FRnv5E-_ufQb5BrFW6lXSN4k-zp7Ba5-L7KzN8mP7r0o8zifD490_FLCrg8SrX9BkYGv07wXX2U20emLj7VMa34SFM6RA-gRU5N-pkCIKU95LWQakOhR_pJJrrY0DyhPTCq1O4htQP9MNcTaTPalwU0dtU0ptOMDuX0VOKZmnQA6-tlsZxO0o0CJyv3ANATQyK7ukNG_d7waGBXJ0HYind4Ybs-ix1AqlGnE_IgBsgi4RMG7bZyeCIdFyZVR6uExTIIdMKjqM2llCEYG-BJgGR3SSPLM32fUN9VUeAoxlisPTdyO44TKkd6TLpcuYmyyIutRQhV0aTjaR2pgOUSGo8AVRgVWORpLbow3CDnCXWMUmuRSqWlCGpTbFVat-CGO4haFnm9Y4iiCi8rob8HoNCNFADfsH4ASRXhEgpMQgtMHiOvG_ddizzZ2q6AuIHJINBCvl4JwGkhYNc2B5l7xpbrf-hitjYIfYsEO1ZeCyAn-W5LNv1acpPD_Ml8z7PIs9of_v5sHvyT1ENyGYdp3ns9Io1iudaPAQkW0SHZfzt2Diu__wl8Il8Y |
| linkProvider | Unpaywall |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bi9NAFB7WrnhBvF_ijVH3wQfTNplk0uCLdelSBNeiLawgDJPJpKamSWlT1u5v8kd6TiYNVlcQKTSUOUw6OZf5JufMN4Qc6JB5CUPK2VAx2-McfM7X0k5YAvBBujpOKrbPYz6ceO9O_JM98nq7FwbLKmeAi6YaL-1p0Z4tOvVD7MwkLNa9DoMvgcx1Tkcs4uQC2eeYXWqR_cnxqP-5WmJ5EF28Kg4j4RgyyDLDK-QDRMCO2lUHO7PRRXPjq-Ta3CRJDFnFedjzzxLKy-t8ITenMst-mZ-ObpAv25GZspRv7XUZtdXZb6SP_zn0m-R6jVtp3wjeIns6v00uva8z83fIjz79KPO4mKdnOn5FAZdHmbbfwsjg1wjf1UeFfWjq4jMd05qPNKNj9ABaFtSknykAUjpAXgupNhR6pJ9kossNLRI6AKPK7AFSO9APcz2VNqNHsoTGvkpjmuZ0LNNTiWdq0iGsr5flMp1mGwVOVu0BoCNDIru6SyZHg_Hh0K5PgrAV7_HSdn0WO4BUo14v5EEMkEXCJwy6XeXwRDouTKqOVgmLZRDohEdRl0spQzA2wJMAye6RVl7k-gGhvquiwFGMsVh7buT2HCdUjvSYdLlyE2WRl1uLEKqmScfTOjIByyU0HgGqMCqwyPNGdGG4Qc4T6hmlNiK1SisR1KbYqrRpwQ13ELUs8mbHEEUdXlZCfw9AoRspAL5h_QCSKsIlFJiEFpg8Rl437rsWeba1XQFxA5NBoIVivRKA00LArl0OMveNLTf_0MVsbRD6Fgl2rLwRQE7y3ZY8_Vpxk8P8yXzPs8iLxh_-_mwe_pPUI3IFh2neez0mrXK51k8ACZbR09rjfwJHPF4n |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+Randomized%2C+Double-Blind%2C+Placebo-Controlled+Clinical+Trial+to+Assess+the+Efficacy+and+Safety+of+Ethyl-Ester+Omega-3+Fatty+Acid+in+Taiwanese+Hypertriglyceridemic+Patients&rft.jtitle=Journal+of+atherosclerosis+and+thrombosis&rft.au=Su%2C+Ta-Chen&rft.au=Hwang%2C+Juey-Jen&rft.au=Huang%2C+Kuo-Chin&rft.au=Chiang%2C+Fu-Tien&rft.date=2017-01-01&rft.issn=1880-3873&rft.eissn=1880-3873&rft.volume=24&rft.issue=3&rft.spage=275&rft_id=info:doi/10.5551%2Fjat.34231&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1340-3478&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1340-3478&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1340-3478&client=summon |